Analyses directory
Laboratoriumsmedizin
Humangenetik
- Myeloid, atypical chronic myelogenic leukemia, chronic neutrophilic leukemia, NGS panel
- AML / Myeloid, acute myeloid leukemia - prognostic panel 1, NGS
- AML / Myeloid, acute myeloid leukemia - panel 2 other therapeutic options, NGA panel
- AML / Myeloid, acute myeloid leukemia - panel 3 sensitive for sAML and prognostic, NGS panel
- Lymphoid, chronic lymphocytic leukemia, prognostic NGS panel
- BCR-ABL t(9;22)
- CBFB-MYH11 inv(16)
- CBFB-MYH11 inv(16) fusion type A
- CCAAT / enhancer-binding protein, alpha (CEBPA)
- Chronic neutrophilia caused by heterozygous mutation in the CSF3R gene
- Chronic lymphoblastic leukemia (B cell): prognostic markers IGHV, TP53, SF3B1, NOTCH1
- Myeloid, chronic myelomonocytic leukemia: core panel diagnostic and prognostic, NGS
- FIP1L1/PDGFRA fusion gene (microdeletion 4q12)
- FLT3 gene: FMS-related tyrosine kinase 3, qualitative
- KIT mutations verification in the case of AML
- Immunoglobulin heavy chains variable gene cluster, IGHV
- Clonality verification T-cell receptor, beta and gamma chain (TCRB, TCRG)
- Large granular lymphocytic leukemia, T-LGL and NK-LGL: STAT3 mutations
- Lymphoid, unclear disease entity - NGS panel
- Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, AHN panel, NGS
- Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, prognostic panel small, NGS panel
- Myeloid, myelodysplastic syndrome with isolated del(5q), markers with therapeutic relevance, NGS panel
- Myeloid, myelodysplastic/myeloproliferative neoplasms, MDS / MPN overlap, NGS panel
- Myeloid, myelodysplastic syndrome MDS diagnostic, NGS panel
- Myeloid, myelodysplastic syndrome MDS - prognostic markers, NGS panel
- Myeloid, myelodysplastic syndrome MDS, markers with therapeutic relevance, NGS panel
- MLL / MLL-PTD (partial Tandem duplication)
- MLL-MLLT2 (AF4) Transcripts(4;11)(q21;q23) in the case of ALL
- MPL mutations in the case of thrombocytopenia or myelofibrosis
- Myeloid, myeloproliferative neoplasia, NGS panel 1
- Myeloid, myeloproliferative neoplasia, extended diagnosis panel, NGS panel 2
- Myeloid, myeloproliferative neoplasia, extended prognostic panel, NGS
- Multiplex aberration screening, 28 markers (for AML, ALL, CML)
- Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel according to MIPSS70 or MIPSS70 plus, NGS panel
- Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel MIPSS70 or MIPSS70 plus extended, NGS panel
- Myeloid, unclear disease entity, NGS panel
- Myeloid neoplasias (AML, CMML, MDS, MPN) - mutation screening
- PML/RAR alpha t(15;17)
- PML/RAR alpha t(15;17) quantitative, L type (BCR1), S type (BCR3) and V type (BCR2)
- AA / myeloid, Aplastic Anemia - prognostic and therapeutic markers, NGS panel
- Myeloid, myeloproliferative neoplasia, polycythemia vera - prognostic panel, NGS
- Polycythemia vera (PV)
- RUNX1 mutation verification
- RUNX1-RUNX1T1 t(8;21) / AML1-ETO t(8;21)
- RUNX1-RUNX1T1 t(8;21)(q22;q22), quantitative / AML1-ETO
Mikrobiologie
Attention
Submissions of sample material from foreign countries should always be carried out by air freight /airmail. Especially in analyses of microbiology as well as haemostaseology long transport distances can lead to inaccuracy of the analysis results.
Please note
Please refer to the pre-analysis notes for each test. The high quality of our analysis results depends also on whether the respective instructions for the preanalysis of the single tests are observed.
Prices
On request, we will be pleased to send you an individual offer for your demanded analyses.